246 related articles for article (PubMed ID: 11595706)
21. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
[TBL] [Abstract][Full Text] [Related]
22. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Esteller M; Sanchez-Cespedes M; Rosell R; Sidransky D; Baylin SB; Herman JG
Cancer Res; 1999 Jan; 59(1):67-70. PubMed ID: 9892187
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.
Kwong J; Lo KW; To KF; Teo PM; Johnson PJ; Huang DP
Clin Cancer Res; 2002 Jan; 8(1):131-7. PubMed ID: 11801549
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
Murao K; Kubo Y; Ohtani N; Hara E; Arase S
Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
[TBL] [Abstract][Full Text] [Related]
26. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients.
Wong IH; Lo YM; Yeo W; Lau WY; Johnson PJ
Clin Cancer Res; 2000 Sep; 6(9):3516-21. PubMed ID: 10999738
[TBL] [Abstract][Full Text] [Related]
27. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma.
Mandelker DL; Yamashita K; Tokumaru Y; Mimori K; Howard DL; Tanaka Y; Carvalho AL; Jiang WW; Park HL; Kim MS; Osada M; Mori M; Sidransky D
Cancer Res; 2005 Jun; 65(11):4963-8. PubMed ID: 15930319
[TBL] [Abstract][Full Text] [Related]
28. Detection of p16 promoter methylation in the serum of oral cancer patients.
Nakahara Y; Shintani S; Mihara M; Hino S; Hamakawa H
Int J Oral Maxillofac Surg; 2006 Apr; 35(4):362-5. PubMed ID: 16298513
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.
Carvalho AL; Jeronimo C; Kim MM; Henrique R; Zhang Z; Hoque MO; Chang S; Brait M; Nayak CS; Jiang WW; Claybourne Q; Tokumaru Y; Lee J; Goldenberg D; Garrett-Mayer E; Goodman S; Moon CS; Koch W; Westra WH; Sidransky D; Califano JA
Clin Cancer Res; 2008 Jan; 14(1):97-107. PubMed ID: 18172258
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
31. Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma.
Fukuoka T; Hibi K; Nakao A
Anticancer Res; 2006; 26(5A):3333-5. PubMed ID: 17094449
[TBL] [Abstract][Full Text] [Related]
32. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.
Wakabayashi T; Natsume A; Hatano H; Fujii M; Shimato S; Ito M; Ohno M; Ito S; Ogura M; Yoshida J
Neurosurgery; 2009 Mar; 64(3):455-61; discussion 461-2. PubMed ID: 19240607
[TBL] [Abstract][Full Text] [Related]
33. The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas.
Huang MJ; Yeh KT; Shih HC; Wang YF; Lin TH; Chang JY; Shih MC; Chang JG
Int J Mol Med; 2002 Nov; 10(5):551-4. PubMed ID: 12373290
[TBL] [Abstract][Full Text] [Related]
34. Modes of silencing of p16 in development of esophageal squamous cell carcinoma.
Tokugawa T; Sugihara H; Tani T; Hattori T
Cancer Res; 2002 Sep; 62(17):4938-44. PubMed ID: 12208744
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas.
Temam S; Bénard J; Dugas C; Trassard M; Gormally E; Soria JC; Faivre S; Luboinski B; Marandas P; Hainaut P; Lenoir G; Mao L; Janot F
Clin Cancer Res; 2005 Apr; 11(7):2547-51. PubMed ID: 15814632
[TBL] [Abstract][Full Text] [Related]
37. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3.
Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y
Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577
[TBL] [Abstract][Full Text] [Related]
38. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma.
Maesawa C; Tamura G; Nishizuka S; Ogasawara S; Ishida K; Terashima M; Sakata K; Sato N; Saito K; Satodate R
Cancer Res; 1996 Sep; 56(17):3875-8. PubMed ID: 8752149
[TBL] [Abstract][Full Text] [Related]
40. [The relationship between methylation of p16 INK 4/CDKN2 gene in promoter region and progress of squamous cell carcinoma of buccal mucosa].
Dong YY; Wang J; Dong FS; Wang X; Li HX; Gu HT
Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 May; 41(5):297-8. PubMed ID: 16784614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
